A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

NCT06232252 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-06-25

No results posted yet for this study

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 765423 in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

BI 765423

BI 765423

DRUG

Placebo matching BI 765423

Placebo matching BI 765423

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2025-04-25
Completion
2025-04-29

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06232252 on ClinicalTrials.gov